Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exebacase (Primary)
  • Indications Bacteraemia; Bacterial endocarditis; Methicillin-resistant Staphylococcus aureus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms DISRUPT
  • Sponsors ContraFect

Most Recent Events

  • 28 Aug 2023 According to a ContraFect media release, Garrett Nichols, MD, Interim Chief Medical Officer of company, will discuss clinical results of Exebacase in this phase 3 trial for CF-370 at the World Anti-Microbial (AMR) Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.
  • 31 Mar 2023 According to a ContraFect media release, contract research organizations (CROs) to support the continued closure of this trial.
  • 19 Dec 2022 According to a ContraFect media release, full results and the clinical study report are expected in the first quarter of 2023. The company is planning a virtual fireside chat in the first quarter of 2023 for an in-depth review and discussion of the DISRUPT study

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top